{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:49:51Z","timestamp":1764402591338},"reference-count":47,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.vaccine.2013.09.005","type":"journal-article","created":{"date-parts":[[2013,9,19]],"date-time":"2013-09-19T19:11:12Z","timestamp":1379617872000},"page":"5359-5365","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The risk of fever following one dose of trivalent inactivated influenza vaccine in children aged \u22656 months to &lt;36 months: A comparison of published and unpublished studies"],"prefix":"10.1016","volume":"31","author":[{"given":"Marlena C.","family":"Kaczmarek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uyen T.","family":"Duong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heath A.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.09.005_bib0005","article-title":"The cost of community-managed viral respiratory illnesses in a cohort of healthy preschool-aged children","volume":"911","author":"Lambert","year":"2008","journal-title":"Respir Res"},{"issue":"24","key":"10.1016\/j.vaccine.2013.09.005_bib0010","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1056\/NEJMoa051721","article-title":"Influenza-associated deaths among children in the United States, 2003\u20132004","volume":"353","author":"Bhat","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0015","series-title":"The Australian immunisation handbook","author":"Australian Government Department of Health and Ageing","year":"2008"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0020","series-title":"Canadian immunization guide: part 3 \u2013 recommended immunisation","author":"Public Health Agency of Canada","year":"2012"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0025","series-title":"Recommended immunizations for children from birth through 6 years old","author":"Centers for Disease Control and Prevention","year":"2012"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0030","series-title":"Green book: chapter 19 \u2013 influenza","author":"Department of Health","year":"2012"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0035","series-title":"Vaccination schedules","author":"European Centre for Disease Prevention and Control","year":"2012"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0040","series-title":"JCVI statement on the routine annual vaccination programme \u2013 extension of the programme to children \u2013 25 July 2013","author":"Department of Health","year":"2013"},{"issue":"3","key":"10.1016\/j.vaccine.2013.09.005_bib0045","first-page":"259","article-title":"Annual report: surveillance of adverse events following immunisation in Australia, 2009","volume":"34","author":"Mahajan","year":"2010","journal-title":"Commun Dis Intell"},{"issue":"3","key":"10.1016\/j.vaccine.2013.09.005_bib0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/01.inf.0000116292.46143.d6","article-title":"Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination","volume":"23","author":"Zangwill","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0055","series-title":"Investigation into febrile reactions in young children following 2010 seasonal trivalent influenza vaccination: status report as at 2 July 2010","author":"Therapeutic Goods Administration","year":"2010"},{"issue":"1","key":"10.1016\/j.vaccine.2013.09.005_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2010-000016","article-title":"Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine","volume":"1","author":"Armstrong","year":"2011","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0065","series-title":"ATAGI Statement: clinical advice for immunisation providers on resumption of the use of 2010 trivalent seasonal vaccines in children less than 5 years of age: 30 July 2010","author":"Australian Government Department of Health and Ageing","year":"2010"},{"issue":"16","key":"10.1016\/j.vaccine.2013.09.005_bib0070","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1001\/jama.296.16.1990","article-title":"Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old","volume":"296","author":"Hambidge","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.vaccine.2013.09.005_bib0075","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1542\/peds.2010-2777","article-title":"Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months","volume":"128","author":"Skowronski","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0080","series-title":"NCT00710866: influenza vaccine dose\u2013response in infants and toddlers: immunogenicity and reactogenicity (TITRE)","author":"U.S. National Institutes of Health","year":"2009"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0085","series-title":"NCT00825162: safety study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged \u22656 months to <18 years","author":"U.S. National Institutes of Health","year":"2010"},{"issue":"5","key":"10.1016\/j.vaccine.2013.09.005_bib0090","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/irv.12107","article-title":"Safety and tolerability of a 2009 trivalent inactivated split-viron influenza vaccine in infants, children and adolescents","volume":"7","author":"Lambert","year":"2013","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0095","series-title":"NCT00858468: safety and immunogenicity testing of influenza vaccine in healthy children 2 months and 6 months of age","author":"U.S. National Institutes of Health","year":"2006"},{"issue":"15","key":"10.1016\/j.vaccine.2013.09.005_bib0100","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1010331","article-title":"Oil-in-water emulsion adjuvant with influenza vaccine in young children","volume":"365","author":"Vesikari","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2013.09.005_bib0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1750-2659.2009.00108.x","article-title":"Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children","volume":"3","author":"Nolan","year":"2009","journal-title":"Influenza Other Respi Viruses"},{"issue":"6","key":"10.1016\/j.vaccine.2013.09.005_bib0110","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1542\/peds.2005-2607","article-title":"Solicited adverse events after influenza immunization among infants, toddlers, and their household contacts","volume":"117","author":"Skowronski","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0115","series-title":"NCT00764790: immunogenicity and safety of GSK Biologicals\u2019 influenza vaccine versus a licensed comparator in children","author":"U.S. National Institutes of Health","year":"2012"},{"issue":"49","key":"10.1016\/j.vaccine.2013.09.005_bib0120","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1016\/j.vaccine.2012.09.069","article-title":"The immunogenicity and safety of a single 0.5mL dose of virosomal subunit influenza vaccine administered to unprimed children aged \u22656 to <36 months: data from a randomized, phase III study","volume":"30","author":"Esposito","year":"2012","journal-title":"Vaccine"},{"issue":"38","key":"10.1016\/j.vaccine.2013.09.005_bib0125","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1016\/j.vaccine.2010.07.041","article-title":"A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6\u201335 months","volume":"28","author":"Esposito","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2013.09.005_bib0130","first-page":"351","article-title":"Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children","volume":"67","author":"Aguero","year":"2007","journal-title":"Medicina (Mex)"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0135","series-title":"NCT00391391: study of inactivated, split-virion influenza vaccine compared with standard Fluzone vaccine in infants and children","author":"U.S. National Institutes of Health","year":"2011"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0140","series-title":"NCT00258817: phase IV trial to collect safety data and sera in healthy children given fluzone vaccine","author":"U.S. National Institutes of Health","year":"2006"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0145","series-title":"NCT00390884: safety and immunogenicity of Fluzone\u00ae vaccine in children who received 2 doses of the 2005\u20132006 fluzone formulation","author":"U.S. National Institutes of Health","year":"2007"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0150","series-title":"NCT00389857: trial to collect safety data and sera for immunogenicity testing","author":"U.S. National Institutes of Health","year":"2007"},{"issue":"4","key":"10.1016\/j.vaccine.2013.09.005_bib0155","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1542\/peds.2004-2373","article-title":"A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children","volume":"115","author":"Englund","year":"2005","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2013.09.005_bib0160","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/adc.83.6.488","article-title":"Safety and immunogenicity of a paediatric presentation of an influenza vaccine","volume":"83","author":"Gonzalez","year":"2000","journal-title":"Arch Dis Child"},{"issue":"10","key":"10.1016\/j.vaccine.2013.09.005_bib0165","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.vaccine.2005.10.008","article-title":"Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip","volume":"24","author":"Delore","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0170","series-title":"NCT00836953: study to collect sera for immunogenicity testing in children vaccinated with Fluzone\u00ae","author":"U.S. National Institutes of Health","year":"2004"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0175","series-title":"NCT00561002: phase IV trial to collect safety data and sera for immunogenicity testing in healthy children given Fluzone\u00ae Vaccine","author":"U.S. National Institutes of Health","year":"2008"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0180","series-title":"NCT00959049: a study to determine the immunogenicity and safety profile of CSL Limited's influenza virus vaccine compared to a US Licensed Comparator influenza virus vaccine in a pediatric population","author":"U.S. National Institutes of Health","year":"2011"},{"issue":"5","key":"10.1016\/j.vaccine.2013.09.005_bib0185","doi-asserted-by":"crossref","first-page":"662","DOI":"10.4161\/hv.19478","article-title":"Parental views on vaccine safety and future vaccinations of children who experienced an adverse event following routine or seasonal influenza vaccination in 2010","volume":"8","author":"Parrella","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2013.09.005_bib0190","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1542\/peds.2006-0725","article-title":"Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care","volume":"118","author":"Vesikari","year":"2006","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2013.09.005_bib0195","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/1471-2334-11-291","article-title":"Relationship between the population incidence of febrile convulsions in young children in Sydney, Australia and seasonal epidemics of influenza and respiratory syncytial virus, 2003-2010: a time series analysis","volume":"11","author":"Polkinghorne","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"51","key":"10.1016\/j.vaccine.2013.09.005_bib0200","doi-asserted-by":"crossref","first-page":"9467","DOI":"10.1016\/j.vaccine.2011.10.029","article-title":"Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study","volume":"29","author":"Stowe","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2013.09.005_bib0205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1542\/peds.2004-1519","article-title":"Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990\u20132003","volume":"115","author":"McMahon","year":"2005","journal-title":"Pediatrics"},{"issue":"16","key":"10.1016\/j.vaccine.2013.09.005_bib0210","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1016\/j.vaccine.2011.02.012","article-title":"Fever following administration of two inactivated influenza vaccines \u2013 a survey of parents of New Zealand infants and children 5 years of age and under","volume":"29","author":"Petousis-Harris","year":"2011","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2013.09.005_bib0215","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1016\/j.vaccine.2012.05.052","article-title":"Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance","volume":"30","author":"Petousis-Harris","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0220","series-title":"NCT00831675: study of safety and immunogenicity of Fluzone\u00ae in healthy children","author":"U.S. National Institutes of Health","year":"2006"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0225","series-title":"NCT00885105: evaluation of responses to Fluzone\u00ae in infants \u22656 months of age who did or did not receive Fluzone\u00ae at 2 months of age","author":"U.S. National Institutes of Health","year":"2006"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0230","series-title":"NCT01096056: trial to evaluate the safety and the immunogenicity of GSK Biologicals\u2019 influenza vaccine GSK2186877A in healthy children","author":"U.S. National Institutes of Health","year":"2012"},{"key":"10.1016\/j.vaccine.2013.09.005_bib0235","series-title":"NCT01196026: immunogenicity and safety study of Fluarix\u2122 vaccine in children who have previously been vaccinated with Pandemrix\u2122","author":"U.S. National Institutes of Health","year":"2012"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T23:53:04Z","timestamp":1539388384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13012322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":47,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0264410X13012322"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The risk of fever following one dose of trivalent inactivated influenza vaccine in children aged \u22656 months to <36 months: A comparison of published and unpublished studies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}